4-Chloro-DL-phenylalanine protects against monocrotaline‑induced pulmonary vascular remodeling and lung inflammation

Bai,Yang; Wang,Han-Ming; Liu,Ming; Wang,Yun; Lian,Guo-Chao; Zhang,Xin-Hua; Kang,Jian; Wang,Huai-Liang

doi:10.3892/ijmm.2013.1591

4-Chloro-DL-phenylalanine protects against monocrotaline‑induced pulmonary vascular remodeling and lung inflammation

Authors:
- Yang Bai
- Han-Ming Wang
- Ming Liu
- Yun Wang
- Guo-Chao Lian
- Xin-Hua Zhang
- Jian Kang
- Huai-Liang Wang
View Affiliations

Affiliations: Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, P.R. China, National Key Subject, Institute of Respiratory Diseases, China Medical University, Shenyang, P.R. China
Published online on: December 16, 2013 https://doi.org/10.3892/ijmm.2013.1591
Pages: 373-382

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was performed to investigate the effects of 4-chloro-DL-phenylalanine (PCPA), a tryptophan hydroxylase (Tph) inhibitor (TphI), on pulmonary vascular remodeling and lung inflammation in monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) in rats. Animal models of PAH were established using Sprague-Dawley (SD) rats by a single intraperitoneal injection of MCT (60 mg/kg). PCPA (50 or 100 mg/kg/day) was administered to the rats with PAH. On day 22, hemodynamic measurements and morphological observations of the lung tissues were performed. The levels of Tph-1 and serotonin transporter (SERT) in the lungs were analyzed by immunohistochemistry and western blot analysis. The expression of matrix metalloproteinase (MMP)-2 and MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 and inflammatory cytokines were assayed by western blot analysis. The activity of MMP-2 and MMP-9 was evaluated by gelatin zymography (GZ). MCT markedly promoted PAH, increased the right ventricular hypertrophy index, pulmonary vascular remodeling, lung inflammation and mortality, which was associated with the increased expression of Tph-1, SERT, MMP-2/-9, TIMP-1/-2 and inflammatory cytokines. PCPA markedly attenuated MCT-induced pulmonary vascular remodeling and lung inflammation, inhibited the expression of Tph-1 and SERT and suppressed the expression of MMP-2/-9, TIMP-1/-2, interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and intercellular adhesion molecule-1 (ICAM-1). These findings suggest that the amelioration of MCT-induced pulmonary vascular remodeling and lung inflammation by PCPA is associated with the downregulation of Tph-1, SERT, MMP/TIMP and inflammatory cytokine expression in rats.

View Figures

View References

1	MacLean MR: Pulmonary hypertension and the serotonin hypothesis: where are we now? Int J Clin Pract Suppl. 27–31. 2007. View Article : Google Scholar : PubMed/NCBI
2	Dewachter L, Adnot S, Fadel E, et al: Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. Am J Respir Crit Care Med. 174:1025–1033. 2006. View Article : Google Scholar : PubMed/NCBI
3	Li XQ, Wang HM, Yang CG, Zhang XH, Han DD and Wang HL: Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats. Acta Pharmacol Sin. 32:217–222. 2010.PubMed/NCBI
4	Crapo PM, Medberry CJ, Reing JE, Tottey S, Van der Merwe Y, Jones KE and Badylak SF: Biologic scaffolds composed of central nervous system extracellular matrix. Biomaterials. 33:3539–3547. 2012. View Article : Google Scholar : PubMed/NCBI
5	Wang Y, Han DD, Wang HM, Liu M, Zhang XH and Wang HL: Downregulation of osteopontin is associated with fluoxetine amelioration of monocrotaline-induced pulmonary inflammation and vascular remodelling. Clin Exp Pharmacol Physiol. 38:365–372. 2011. View Article : Google Scholar : PubMed/NCBI
6	Giantin M, Aresu L, Benali S, et al: Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases and vascular endothelial growth factor in canine mast cell tumours. J Comp Pathol. 147:419–429. 2012. View Article : Google Scholar : PubMed/NCBI
7	Umesh A, Paudel O, Cao YN, Myers AC and Sham JS: Alteration of pulmonary artery integrin levels in chronic hypoxia and monocrotaline-induced pulmonary hypertension. J Vasc Res. 48:525–537. 2011. View Article : Google Scholar : PubMed/NCBI
8	Price LC, Wort SJ, Perros F, et al: Inflammation in pulmonary arterial hypertension. Chest. 141:210–221. 2012. View Article : Google Scholar : PubMed/NCBI
9	Tuder RM, Groves B, Badesch DB and Voelkel NF: Exuberant endothelial cell growth and element of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 144:275–285. 1994.PubMed/NCBI
10	Bauer EM, Zheng H, Comhair S, Erzurum S, Billiar TR and Bauer PM: Complement C3 deficiency attenuates chronic hypoxia-induced pulmonary hypertension in mice. PLoS One. 6:e285782011. View Article : Google Scholar : PubMed/NCBI
11	Rashid M, Fahim M and Kotwani A: Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: possible mechanisms. Fundam Clin Pharmacol. 27:271–278. 2013. View Article : Google Scholar : PubMed/NCBI
12	Li M, Riddle SR, Frid MG, et al: Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunol. 187:2711–2722. 2011. View Article : Google Scholar : PubMed/NCBI
13	Guignabert C, Raffestin B, Benferhat R, et al: Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 111:2812–2819. 2005. View Article : Google Scholar : PubMed/NCBI
14	Fanburg BL and Lee SL: A new role for an old molecule: serotonin as a mitogen. Am J Physiol. 272:L795–L806. 1997.PubMed/NCBI
15	Marcos E, Fadel E, Sanchez O, et al: Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res. 94:1263–1270. 2004. View Article : Google Scholar : PubMed/NCBI
16	Eddahibi S, Guignabert C, Barlier-Mur AM, et al: Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation. 113:1857–1864. 2006. View Article : Google Scholar : PubMed/NCBI
17	Morrell NW, Adnot S, Archer SL, et al: Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 54(Suppl 1): S20–S31. 2009. View Article : Google Scholar : PubMed/NCBI
18	Rothman RB, Cadet JL, Dersch CM, et al: Altered gene expression in pulmonary tissue of tryptophan hydroxylase-1 knockout mice: implications for pulmonary arterial hypertension. PLoS One. 6:e177352011. View Article : Google Scholar : PubMed/NCBI
19	Izikki M, Hanoun N, Marcos E, et al: Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 293:L1045–L1052. 2007. View Article : Google Scholar : PubMed/NCBI
20	Margolis KG and Pothoulakis C: Serotonin has a critical role in the pathogenesis of experimental colitis. Gastroenterology. 137:1562–1566. 2009. View Article : Google Scholar : PubMed/NCBI
21	Tucker A, Bryant SE, Frost HH and Miqally N: Chemical sympathectomy and serotonin inhibition reduce monocrotaline-induced right ventricular hypertrophy in rats. Can J Physiol Pharmacol. 61:356–362. 1983. View Article : Google Scholar : PubMed/NCBI
22	Liu M, Wang Y, Wang HM, Bai Y, Zhang XH, Sun YX and Wang HL: Fluoxetine attenuates chronic methamphetamine-induced pulmonary arterial remodeling: possible involvement of serotonin transporter and serotonin 1B receptor. Basic Clin Pharmacol Toxicol. 112:77–82. 2013. View Article : Google Scholar
23	Agard C, Rolli-Derkinderen M, Dumas-de-La-Roque E, et al: Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br J of Pharmacol. 158:1285–1294. 2009. View Article : Google Scholar : PubMed/NCBI
24	Zhang XH, Chen L, Wang HL and Gao J: Methodological study of determination of rat pulmonary artery pressure. J Chin Med Univ. 33:388–389. 2004.(in Chinese).
25	Wang HM, Wang Y, Liu M, Bai Y, Zhang XH and Wang HL: Fluoxetine inhibits monocrotaline-induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling pathways in rats. Can J Physiol Pharmacol. 90:1506–1515. 2012. View Article : Google Scholar : PubMed/NCBI
26	Herve P, Launay JM, Scrobohaci ML, et al: Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 99:249–254. 1995. View Article : Google Scholar : PubMed/NCBI
27	Hironaka E, Hongo M, Sakai A, et al: Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res. 60:692–699. 2003. View Article : Google Scholar : PubMed/NCBI
28	Morecroft I, White K, Caruso P, et al: Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension. Mol Ther. 20:1516–1528. 2012. View Article : Google Scholar : PubMed/NCBI
29	Fligny C, Fromes Y, Bonnin P, et al: Maternal serotonin influences cardiac function in adult offspring. FASEB J. 22:2340–2349. 2008. View Article : Google Scholar : PubMed/NCBI
30	MacLean MR and Dempsie Y: Serotonin and pulmonary hypertension-from bench to bedside? Curr Opin Pharmacol. 9:281–286. 2009. View Article : Google Scholar : PubMed/NCBI
31	Walther DJ, Peter JU, Bashammakh S, Hortnaql H, Voits M, Fink H and Bader M: Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 299:762003. View Article : Google Scholar : PubMed/NCBI
32	Valzelli L, Bernasconi S and Dalessandro M: Time-courses of p-CPA-induced depletion of brain serotonin and muricidal aggression in the rat. Pharmacol Res Commun. 15:387–395. 1983. View Article : Google Scholar : PubMed/NCBI
33	Ghia JE, Li N, Wang H, et al: Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology. 137:1649–1660. 2009. View Article : Google Scholar : PubMed/NCBI
34	Moreau AW, Amar M, Callebert J and Fossier P: Serotonergic modulation of LTP at excitatory and inhibitory synapses in the developing rat visual cortex. Neuroscience. 238:148–158. 2013. View Article : Google Scholar : PubMed/NCBI
35	Nakadate K, Imamura K and Watanabe Y: C-fos activity mapping reveals differential effects of noradrenaline and serotonin depletion on the regulation of ocular dominance plasticity in rats. Neuroscience. 235:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
36	Song D, Wang HL, Wang S and Zhang XH: 5-Hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells are extracellular signal-regulated kinase pathway dependent. Acta Pharmacol Sin. 26:563–567. 2005. View Article : Google Scholar
37	Zhai FG, Zhang XH and Wang HL: Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of kv1.5 channels in rats. Clin Exp Pharmacol Physiol. 36:850–856. 2009. View Article : Google Scholar
38	Rattray M, Baldessari S, Gobbi M, Mennini T, Samanin R and Bendotti C: p-Chlorophenylalanine changes serotonin transporter mRNA levels and expression of the gene product. J Neurochem. 67:463–472. 1996. View Article : Google Scholar : PubMed/NCBI
39	Chelladurai P, Seeger W and Pullamsetti SS: Matrix metalloproteinases and their inhibitors in pulmonary hypertension. Eur Respir J. 40:766–782. 2012. View Article : Google Scholar : PubMed/NCBI
40	Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H and Hara Y: Captopril attenuates matrix metalloproteinase-2 and −9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci. 108:487–494. 2008.
41	Karthikeyan VJ, Lane DA, Beevers DG, Lip GY and Blann AD: Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications. J Hum Hypertens. 27:72–78. 2013. View Article : Google Scholar : PubMed/NCBI
42	Wang HL: The serotonin receptor and transporter are potential therapeutic targets for pulmonary hypertension. Curr Opin Investig Drugs. 5:963–966. 2004.PubMed/NCBI
43	Shum JK, Melendez JA and Jeffrey JJ: Serotonin-induced MMP-13 production is mediated via phospholipase C, protein kinase C, and ERK1/2 in rat uterine smooth muscle cells. J Biol Chem. 277:42830–42840. 2002. View Article : Google Scholar : PubMed/NCBI
44	Witzenrath M, Ahrens B, Kube SM, et al: Allergic lung inflammation induces pulmonary vascular hyperresponsiveness. Eur Respir J. 28:370–377. 2006. View Article : Google Scholar : PubMed/NCBI
45	Hassoun PM, Mouthon L, Barbera JA, et al: Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 54(Suppl 1): S10–S19. 2009. View Article : Google Scholar : PubMed/NCBI
46	Mikulski Z, Zaslona Z, Cakarova L, et al: Serotonin activates murine alveolar macrophages through 5-HT2C receptors. Am J Physiol Lung Cell Mol Physiol. 299:L272–L280. 2010. View Article : Google Scholar : PubMed/NCBI
47	Lima C, Souza VM, Soares AL, Macedo MS, Tavares-de-Lima W and Vargaftig BB: Interference of methysergide, a specific 5-hydroxytryptamine receptor antagonist, with airway chronic allergic inflammation and remodeling in a murine model of asthma. Clin Exp Allergy. 37:723–734. 2007. View Article : Google Scholar : PubMed/NCBI
48	Kushnir-Sukhov NM, Gilfillan AM, Coleman JW, Brown JM, Bruening S, Toth M and Metcalfe DD: 5-hydroxytryptamine induces mast cell adhesion and migration. J Immunol. 177:6422–6432. 2006. View Article : Google Scholar : PubMed/NCBI
49	Lawrie A, Waterman E, Southwood M, et al: Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol. 172:256–264. 2008. View Article : Google Scholar : PubMed/NCBI
50	Wilkins MR: Pulmonary hypertension: the science behind the disease spectrum. Eur Respir Rev. 21:19–26. 2012. View Article : Google Scholar : PubMed/NCBI